Rx semaglutide Wegovy (semaglutide) is a GLP-1 injection for weight loss
Most menopausal women report 25-30% fewer hot flashes after losing 5-10% of body weighta goal semaglutide typically achieves within 2-3 months
The formulation pairs a stabilized GHRH receptor agonist with a selective growth hormone secretagogue receptor (GHS-R) agonist, allowing concurrent investigation of GHRH and ghrelin / GHS pathway activation
Our rankings are based on medical standards and patient care quality
Competing interests DB received presentation fees (TEVA, Novartis and Pfizer), travel fees (Allergan, TEVA, Pfizer, Abbvie and Lundbeck), advisory board fees (Novartis, Lilly, Teva, Lundbeck, Pfizer and Abbvie) and participated in clinical trials (TEVA, Lundbeck, Novartis, Lilly and Novo Nordisk Foundation) outside of the submitted work